We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

76 hedge funds and large institutions have $29.3M invested in Outlook Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 26 increasing their positions, 18 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 18

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

16% more capital invested

Capital invested by funds: $25.3M → $29.3M (+$4.01M)

1% more funds holding

Funds holding: 75 → 76 (+1)

0.02% less ownership

Funds ownership: 0.55% → 0.53% (-0.02%)

Holders
76
Holders Change
+1
Holders Change %
+1.33%
% of All Funds
1.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
26
Reduced
18
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$188K
2
AA
Ancora Advisors
Ohio
+$101K
3
State Street
State Street
Massachusetts
+$69.4K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$41.7K
5
Squarepoint
Squarepoint
New York
+$37.3K

Top Sellers

Rank Fund Capital Flow
1
VF
Vista Finance
Missouri
-$724K
2
Renaissance Technologies
Renaissance Technologies
New York
-$187K
3
Millennium Management
Millennium Management
New York
-$183K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$179K
5
BlackRock
BlackRock
New York
-$115K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$8.36M -$115K -4,955 -1%
Vanguard Group
2
Vanguard Group
Pennsylvania
$6.85M -$2.6K -112 -0%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$2.52M +$6.86K +295 +0.3%
State Street
4
State Street
Massachusetts
$2.38M +$69.4K +2,986 +3%
LA
5
LVW Advisors
New York
$2.12M – – –
Northern Trust
6
Northern Trust
Illinois
$1.19M +$1.67K +72 +0.1%
N
7
Nuveen
North Carolina
$1.02M +$9.7K +417 +1%
VF
8
Vista Finance
Missouri
$485K -$724K -31,141 -61%
Bank of New York Mellon
9
Bank of New York Mellon
New York
$437K +$30.2K +1,298 +8%
Charles Schwab
10
Charles Schwab
California
$402K -$2K -86 -0.5%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$240K -$179K -7,680 -44%
GCP
12
GSA Capital Partners
United Kingdom
$205K +$3.25K +140 +2%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$197K +$188K +8,088 New
LNC
14
Lincoln National Corp
Pennsylvania
$187K – – –
FMC
15
First Merchants Corp
Indiana
$182K – – –
RhumbLine Advisers
16
RhumbLine Advisers
Massachusetts
$178K +$11.9K +510 +8%
Wells Fargo
17
Wells Fargo
California
$172K +$14.9K +639 +10%
Millennium Management
18
Millennium Management
New York
$162K -$183K -7,883 -54%
AA
19
Ancora Advisors
Ohio
$132K +$101K +4,325 +393%
LPL Financial
20
LPL Financial
California
$123K -$907 -39 -0.8%
Goldman Sachs
21
Goldman Sachs
New York
$115K -$12.3K -529 -10%
Bank of America
22
Bank of America
North Carolina
$113K +$1.02K +44 +1%
JP Morgan Chase
23
JP Morgan Chase
New York
$79K +$1.56K +67 +2%
GCM
24
Gables Capital Management
Florida
$75K – – –
Morgan Stanley
25
Morgan Stanley
New York
$75K +$14.2K +609 +24%
1
2 3 4

OTLK Hedge Fund Activity: Q3 2022 in Review

76 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q3 2022, worth a combined $29.3M — up 16% from $25.3M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new OTLK positions and 5 closed out — a net gain of 2 holders — while 26 added to existing stakes and 18 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $188K. The largest seller was Vista Finance, cutting an estimated $724K.

  • 76 institutional investors held Outlook Therapeutics (OTLK) as of Q3 2022, up from 75 in Q2 2022.
  • Funds reported $29.3M of Outlook Therapeutics stock for Q3 2022, up 16% quarter-over-quarter.
  • 7 funds opened new Outlook Therapeutics positions in Q3 2022 and 5 closed out, a net change of +2 holders.
  • The largest Outlook Therapeutics buyer in Q3 2022 was Fidelity Investments, an estimated $188K added.
  • The largest Outlook Therapeutics seller in Q3 2022 was Vista Finance, an estimated $724K sold.

Based on aggregated 13F filings for Q3 2022.